Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

Underwriters have a 30-day option to purchase extra 1.13 million shares from present owners at IPO price. Beta Bionics will ...

Although the system does automatically adjust insulin delivery based on blood glucose ... which in turn sends data to a mobile device. It can last for up to 90 days. The addition of TypeZero ...

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people ...

1 In contrast with antepartum, where exposure of the fetus to maternal hyperglycaemia is a major consideration, following delivery of the baby ... However, evidence from studies with a range of ...

Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and ...

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the ...